Comorbidity of attention deficit-hyperactivity disorder and substance use disorder
Cuneyt Evren
Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2018;31:115-124
PDF
Article No: 0   Article Type :  Editorial
REFERENCES
1.Wilens TE, Fusillo S. When ADHD and substance use disorders intersect: relationship and treatment implications. Curr Psychiatry Rep 2007; 9:408-414.

2.Bukstein OG. Attention Deficit Hyperactivity Disorder and Substance Use Disorders: In Stanford C, Tannock R (editors). Behavioral Neuroscience of Attention Deficit Hyperactivity Disorder and Its Treatment, Current Topics in Behavioral Neurosciences 9. Springer-Verlag Berlin Heidelberg 2012, 145-172.

3.Dennis M, Godley SH, Diamond G, Tims FM, Babor T, Donaldson J, Liddle H, Titus JC, Kaminer Y, Webb C, Hamilton N, Funk R. The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. J Subst Abuse Treat 2004; 27:197-213.

4.van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle CL, Swets M, Schoevers RA. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend 2012; 122:11-19.

5.van de Glind G, Van Emmerik-van Oortmerssen K, Carpentier PJ, Levin FR, Koeter MW, Barta C, Kaye S, Skutle A, Franck J, Konstenius M, Bu ET, Moggi F, Dom G, Demetrovics Z, Fatséas M, Schillinger A, Kapitány-Fövény M, Verspreet S, Seitz A, Johnson B, Faraone SV, Ramos-Quiroga JA, Allsop S, Carruthers S, Schoevers RA; Iasp Research Group, van den Brink W. The International ADHD in Substance Use Disorders Prevalence (IASP) study: background, methods and study population. Int J Methods Psychiatr Res 2013;22:232-244.

6.Evren C, Umut G, Bozkurt M, Can Y, Evren B, Agachanli R. Partial mediator role of physical abuse on the relationship between ADHD symptoms and severity of dissociative experiences in a sample of inpatients with alcohol use disorder. Indian J Psychiatry 2017; 59:306-312.

7.Evren C, Alniak I, Karabulut V, Cetin T, Umut G, Agachanli R, Evren B. Relationship of probable attention deficit hyperactivity disorder with severity of psychopathology and impulsivity in a sample of male patients with opioid use disorder. Psychiatry Investig 2018; 15:164-171.

8.Evren C, Dalbudak E, Evren B, Can Y, Umut G. The severity of attention deficit hyperactivity symptoms and its relationship with lifetime substance use and psychological variables among 10th grade students in Istanbul. Compr Psychiatry 2014; 55:1665-1670.

9.Wilens TE, Martelon M, Joshi G, Bateman C, Fried R, Petty C, Biederman J. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry 2011; 50:543-553.

10.Zulauf CA, Sprich SE, Safren SA, Wilens TE. The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Curr Psychiatry Rep 2014; 16:436.

11.Yargic I, Vardar E. Comorbidity in alcohol and substance use disorders.. (ed. Evren C.) Approach to Alcohol and Substance Disorders and Their Treatment. .Update in Psychiatry, Journal of Psychiatric Association of Turkey for Continuing Education/ Continuing Professional Development 2014; 4:140-150.

12.Arias AJ, Gelernter J, Chan G, Weiss RD, Brady KT, Farrer L, Kranzler HR. Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders. Addict Behav 2008; 33:1199-1207.

13.Moura HF, Faller S, Benzano D, Szobot C, von Diemen L, Stolf AR, Souza-Formigoni ML, Cruz MS, Brasiliano S, Pechansky F, Kessler FH. The effects of ADHD in adult substance abusers. J Addict Dis 2013; 32:252-262.

14.Bozkurt M, Evren C, Umut G, Evren B. Relationship of attention-deficit/hyperactivity disorder symptom severity with severity of alcohol-related problems in a sample of inpatients with alcohol use disorder. Neuropsychiatr Dis Treat 2016; 12:1661-1667.

15.Bozkurt M, Evren C, Umut G, Agachanli R, Evren B. Severity of craving is related with severity of adult ADHD symptoms among inpatients with alcohol use disorder. Anatolian Journal of Psychiatry 2017; 18:13-21.

16.Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015; 385:2190-2196.

17.McAweeney M, Rogers NL, Huddleston C, Moore D, Gentile JP. Symptom prevalence of ADHD in a community residential substance abuse treatment program. J Atten Disord 2010; 13:601-608.

18.McGough JJ, Smalley SL, McCracken JT, Yang M, Del’Homme M, Lynn DE, Loo S. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 2005; 162:1621-1627.

19.Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev 2011; 31:328-341.

20.Kousha M, Shahrivar Z, Alaghband-Rad J. Substance use disorder and ADHD: is ADHD a particularly “specific” risk factor? J Atten Disord 2012; 16:325-332.

21.Chang Z, Lichtenstein P, Larsson H. The effects of childhood ADHD symptoms on early-onset substance use: a Swedish twin study. J Abnorm Child Psychol 2012;40:425-35.

22.Wilens TE, Adamson J, Sgambati S, Whitley J, Santry A, Monuteaux MC, Biederman J. Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD. Am J Addict 2007; 16(Suppl.1):14-21.

23.Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol 2007; 74:1212-1223.

24.Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med 2010; 122:97-109.

25.Whelan R, Conrod PJ, Poline JB, Lourdusamy A, Banaschewski T, Barker GJ, Bellgrove MA, Büchel C, Byrne M, Cummins TD, Fauth-Bühler M, Flor H, Gallinat J, Heinz A, Ittermann B, Mann K, Martinot JL, Lalor EC, Lathrop M, Loth E, Nees F, Paus T, Rietschel M, Smolka MN, Spanagel R, Stephens DN, Struve M, Thyreau B, Vollstaedt-Klein S, Robbins TW, Schumann G, Garavan H. Adolescent impulsivity phenotypes characterized by distinct brain networks. Nat Neurosci 2012; 15:920-925.

26.Biederman J, Petty CR, Wilens TE, Fraire MG, Purcell CA, Mick E, Monuteaux MC, Faraone SV. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2008; 165:107-115.

27.Faraone SV, Biederman J. Neurobiology of attention deficit hyperactivity disorder. In Charney DS, Nestler EJ (editors). Neurobiology of Mental Illness. Second ed. New York, NY: Oxford University Press, 2004.

28.Yule AM, Wilens TE, Martelon MK, Simon A, Biederman J. Does exposure to parental substance use disorders increase substance use disorder risk in offspring? A 5-year follow-up study. Am J Addict 2013; 22:460-465.

29.Bhatara V, Loudenberg R, Ellis R. Association of attention deficit hyperactivity disorder and gestational alcohol exposure: an exploratory study. J Atten Disord 2006; 9:515-522.

30.Schmitz M, Denardin D, Laufer Silva T, Pianca T, Hutz MH, Faraone S, Rohde LA. Smoking during pregnancy and attention-deficit/hyperactivity disorder, predominantly inattentive type: a case-control study. J Am Acad Child Adolesc Psychiatry 2006; 45:1338-1345.

31.Capusan AJ, Bendtsen P, Marteinsdottir I, Kuja-Halkola R, Larsson H. Genetic and environmental contributions to the association between attention deficit hyperactivity disorder and alcohol dependence in adulthood: a large population-based twin study. Am J Med Genet B Neuropsychiatr Genet 2015; 168:414-422.

32.Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152:1652-1658.

33.Biederman J, Wilens T, Mick E, Faraone SV, Weber W, Curtis S, Thornell A, Pfister K, Jetton JG, Soriano J. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1997; 36:21-29.

34.Brook DW, Brook JS, Zhang C, Koppel J. Association between attention-deficit/hyperactivity disorder in adolescence and substance use disorders in adulthood. Arch Pediatr Adolesc Med 2010; 164:930-934.

35.Elkins IJ, McGue M, Iacono WG. Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Arch Gen Psychiatry 2007; 64:1145-1152.

36.Fergusson DM, Horwood LJ, Ridder EM. Conduct and attentional problems in childhood and adolescence and later substance use, abuse and dependence: results of a 25-year longitudinal study. Drug Alcohol Depend 2007; 88(Suppl.1):14-26.

37.van Emmerik-van Oortmerssen K, van de Glind G, Koeter MW, Allsop S, Auriacombe M, Barta C, Bu ET, Burren Y, Carpentier PJ, Carruthers S, Casas M, Demetrovics Z, Dom G, Faraone SV, Fatseas M, Franck J, Johnson B, Kapitány-Fövény M, Kaye S, Konstenius M, Levin FR, Moggi F, Møller M, Ramos-Quiroga JA, Schillinger A, Skutle A, Verspreet S; IASP research group, van den Brink W, Schoevers RA. Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study. Addiction 2014; 109:262-272.

38.Spencer AE, Faraone SV, Bogucki OE, Pope AL, Uchida M, Milad MR, Spencer TJ, Woodworth KY, Biederman J. Examining the association between posttraumatic stress disorder and attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. J Clin Psychiatry 2016; 77:72-83.

39.Endo T, Sugiyama T, Someya T. Attention-deficit/hyperactivity disorder and dissociative disorder among abused children. Psychiatry Clin Neurosci 2006; 60:434-438.

40.Matsumoto T, Imamura F. Association between childhood attention-deficit-hyperactivity symptoms and adulthood dissociation in male inmates: preliminary report. Psychiatry Clin Neurosci 2007; 61:444-446.

41.Evren C, Umut G, Bozkurt M, Evren B, Agachanli R. Mediating role of childhood emotional abuse on the relationship between severity of ADHD and PTSD symptoms in a sample of male inpatients with alcohol use disorder. Psychiatry Res 2016; 239:320-324.

42.Peles E, Schreiber S, Sutzman A, Adelson M. Attention deficit hyperactivity disorder and obsessive-compulsive disorder among former heroin addicts currently in methadone maintenance treatment. Psychopathology 2012; 45:327-333.

43.Kollins SH. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin 2008; 24:1345-1357.

44.Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111:179-185.

45.Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry 2013; 70:740-749.

46.Hammerness P, Joshi G, Doyle R, Georgiopoulos A, Geller D, Spencer T, Petty CR, Faraone SV, Biederman J. Do stimulants reduce the risk for cigarette smoking in youth with attention-deficit hyperactivity disorder? A prospective, long-term, open-label study of extended-release methylphenidate. J Pediatr 2013; 162:22-27.

47.Hammerness P, Petty C, Faraone SV, Biederman J. Do stimulants reduce the risk for alcohol and substance use in youth with ADHD? A secondary analysis of a prospective, 24-month open-label study of osmotic-release methylphenidate. J Atten Disord 2017; 21:71-77.

48.Konstenius M, Jayaram-Lindström N, Guterstam J, Beck O, Philips B, Franck J. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction 2014; 109:440-449.

49.Lichtenstein P, Larsson H. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2013; 368:776.

50.Wilens TE, Morrison NR. The intersection of attention-deficit/hyperactivity disorder and substance abuse. Curr Opin Psychiatry 2011; 24:280-285.

51.Wilens TE, Adler LA, Tanaka Y, Xiao F, D’Souza DN, Gutkin SW, Upadhyaya HP. Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. Curr Med Res Opin 2011; 27:2309-2320.

52.Adler L, Wilens T, Zhang S, Durell T, Walker D, Schuh L, Jin L, Feldman P, Trzepacz P. Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Am J Addict 2009;18:393-401.

53.Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008; 96:145-154.

54.Thurstone C, Riggs PD, Salomonsen-Sautel S, Mikulich-Gilbertson SK. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry 2010; 49:573-582.

55.McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict 2010; 19:481-489.

56.Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, Macdonald M, Lohman M, Bailey GL, Haynes L, Jaffee WB, Haminton N, Hodgkins C, Whitmore E, Trello-Rishel K, Tamm L, Acosta MC, Royer-Malvestuto C, Subramaniam G, Fishman M, Holmes BW, Kaye ME, Vargo MA, Woody GE, Nunes EV, Liu D. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry 2011; 50:903-914.

57.Winhusen TM, Lewis DF, Riggs PD, Davies RD, Adler LA, Sonne S, Somoza EC. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011; 21:455-463.

58.Levin FR, Evans SM, Brooks DJ, Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006; 81:137-148.

59.Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007; 87:20-29.

60.Pérez de los Cobos J, Si-ol N, Pérez V, Trujols J. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. Br J Clin Pharmacol 2014; 77:337-356.

61.Zaso MJ, Park A, Antshel KM. Treatments for adolescents with comorbid ADHD and substance use disorder: a systematic review. J Atten Disord 2015 (DOI 1087054715569280).

62.Cunill R, Castells X, Tobias A, Capellà D. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol 2015; 29:15-23.

63.Crunelle CL, van den Brink W, Veltman DJ, van Emmerik-van Oortmerssen K, Dom G, Schoevers RA, Booij J. Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence. Eur Neuropsychopharmacol 2013; 23:1714-1723.

64.Safren SA, Sprich S, Mimiaga MJ, Surman C, Knouse L, Groves M, Otto MW. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 2010; 304:875-880.

65.van Emmerik-van Oortmerssen K, Vedel E, van den Brink W, Schoevers RA. Integrated cognitive behavioral therapy for patients with substance use disorder and comorbid ADHD: two case presentations. Addict Behav 2015; 45:214-217.

66.Kaye S, Darke S, Torok M. Attention deficit hyperactivity disorder (ADHD) among illicit psychostimulant users: a hidden disorder? Addiction 2013; 108:923-931.
Dusunen Adam The Journal of Psychiatry and Neurological Sciences
Bakırköy Prof. Dr. Mazhar Osman Ruh Sağlığı ve Sinir Hastalıkları Eğitim ve Araştırma Hastanesi
Publisher
Yerküre Tanıtım ve Yayıncılık Hizmetleri A.Ş.